Comments: House: finally worth blogging about!

so, were they right on the brain stuff?

Just curious, because one of my favorite hobbies on the legal shows is to find spots where they're wrong on the law or make some lame strategic move in court...

Posted by KG at February 15, 2006 01:35 PM

Interesting! Thanks for that.

Posted by chanhay at February 15, 2006 08:30 PM

221 B Baker st, eh?

Well, Holmes was based on a doctor Arthur Doyle knew, so it all fits together.

Wilson is Watson, and Weber is Moriarty... where do our other irregulars fit?

Posted by Bill at February 15, 2006 09:00 PM

That's very interesting. Thanks for the run-down.

Although if Weber's drug company wanted to get the drug FDA approved (and they must, that's where the real money is and a drug like this has the potential for some really big bucks) wouldn't they also want it tested in clinical trials in the US or another major country? I could see doing initial trials and publications in India but they would have to know that it needed to be legit before they can make money from it. I thought the bit where a single e-mail from one doctor shutting down a whole line of research rather unbelievable too.

Some universities do look at which journals the articles are published in before assigning merit pay, not just how many publications there are. Mine does anyway.

Just as a footnote, in Canada you know have to register a drug trial when you start it if you want to publish the results later. That's to prevent a company doing 10 studies, 9 of which are negative and one shows an effect and only publishing the one that shows it works.

Posted by Ariadne at February 15, 2006 09:04 PM

Yes, they would still have to go through the FDA, but as the one Glaxo commercial points out, one in a million compounds turns out to be a testable drug. So where can they test the other 999,999? India and other countries similarly situated.

This is also a way to get around the study registration. Studies done outside the country don't always require registration, and the company can tweak the demographics of the study group until they know EXACTLY what will give them the results they are looking for in a registered study.

The single email might have been the straw that broke the camel's back, or House might have presented them with the info from the New Dehli study. The FDA moves slow, but they are pretty good at protecting patients from harmful drugs, hence all the meta-analysis that most IRBs require from clinical studies.

If this was a US study, run through a University hospital, say, then a single email directed at the right person (IRB chair, for example) could halt the study.

BTW, the IRB is the Institutional Review Board, the committee charged by the institution with overseeing the ethical implications of every human research study, including HIIPA concerns, harmfulness of the protocol, inclusion of diverse subjects, etc. The IRB chair usually has broad powers to stop a study in progress or demand justification for questionable practices.

Posted by caltechgirl at February 16, 2006 11:15 AM

Oh, and Bill, While Wilson is definitely Watson, Vogler was Moriarty. Weber is just a silly villain....

Cuddy is Inspector Lestrade.

Stacy is Irene Adler (see A Scandal in Bohemia)

The residents (Foreman, Chase, Cameron) are the Baker St. Irregulars...

and he needs a Mrs. Hudson to clean up after him. Cameron, maybe?

Posted by caltechgirl at February 16, 2006 11:20 AM